MedPath

SpecGx LLC

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

37

FDA:34
NMPA:3

Drug Approvals

Oxycodone and Acetaminophen Tablets

Product Name
泰勒宁
Approval Number
国药准字HJ20181190
Approval Date
Jul 7, 2020
NMPA

Oxycodone and Acetaminophen Tablets

Product Name
泰勒宁
Approval Number
国药准字HJ20181186
Approval Date
Jul 7, 2020
NMPA

Oxycodone and Acetaminophen Tablets

Product Name
泰勒宁
Approval Number
J20171086
Approval Date
Jul 2, 2018
NMPA

Clinical Trials

No trials found

News

FDA Rejects Mallinckrodt's Abuse-Deterrent Roxicodone Reformulation

The FDA issued a Complete Response Letter for SpecGx LLC's abuse-deterrent, immediate-release reformulation of Roxicodone (oxycodone hydrochloride) tablets.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.